iii.MK-1084: The phase 1 KANDLELIT-001 trial evaluated the safety and preliminary antitumor activity of MK-1084, a next-generation, selective KRAS G12C covalent inhibitor in KRAS G12C-mutant CRC and NSCLC tumors, as a monotherapy or in combination with cetuximab or chemotherapy (FOLFLOX).226 While the trial is still ongoing, preliminary data suggest that MK-1084 monotherapy, or in combination with cetuximab and/or chemotherapy, has a manageable safety profile with evidence of antitumor activity. This evidence concerns the gene KRAS and colorectal carcinoma.